Verition Fund Management
MRSN

Verition Fund Management’s Mersana Therapeutics MRSN Stock Holding History

Verition Fund Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,472
Closed -$482K – 3571
2024
Q4 		$482K Sell
13,472
-38,658
-74% -$2M ﹤0.01% 2509
2024
Q3 		$2.46M Buy
52,130
+51,688
+11,694% +$2.28M 0.01% 1295
2024
Q2 		$22.2K Sell
442
-22,125
-98% -$1.6M ﹤0.01% 2861
2024
Q1 		$2.53M Buy
+22,567
New +$2.24M 0.02% 1080
2023
Q4 		– Sell
-6,538
Closed -$208K – 2563
2023
Q3 		$208K Buy
+6,538
New +$311K ﹤0.01% 1957
2022
Q4 		– Sell
-652
Closed -$110K – 2521
2022
Q3 		$110K Buy
+652
New +$106K ﹤0.01% 2609

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Verition Fund Management's MRSN Position: Q1 2025 in Review

Verition Fund Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 13,472 shares — an estimated $482K sold.

Verition Fund Management first reported a position in MRSN in Q3 2022 and held it in 6 quarters. The position peaked at $2.53M in Q1 2024. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Verition Fund Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 13,472 Mersana Therapeutics shares in Q1 2025, an estimated $482K.
  • Verition Fund Management first reported a position in Mersana Therapeutics in Q3 2022 and held it in 6 quarters.
  • Verition Fund Management's Mersana Therapeutics position peaked at $2.53M in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.